TORL BioTherapeutics Welcomes Dr. Anna Berkenblit to the Board
TORL BioTherapeutics LLC (TORL), a clinical-stage biotechnology firm, is excited to announce the appointment of Dr. Anna Berkenblit, MD, MMSc, to its Board of Directors. This strategic addition aims to enhance the company's mission of developing innovative antibody-based immunotherapies that benefit cancer patients globally.
Dr. Berkenblit's Impressive Background
Dr. Berkenblit brings over 20 years of expertise in clinical development focused on pioneering anticancer treatments. Currently, she serves as the Chief Scientific and Medical Officer of the Pancreatic Cancer Action Network (PanCAN). In this role, she spearheads scientific research and clinical strategies to help improve outcomes for cancer patients.
Her previous experience includes her tenure as Chief Medical Officer at ImmunoGen, where she played a pivotal role in developing mirvetuximab soravtansine-gynx. This groundbreaking treatment received FDA approval for patients with FR?-positive platinum-resistant ovarian cancer, showcasing her ability to lead successful research initiatives.
Comments from Leadership
Expressing enthusiasm about Dr. Berkenblit's appointment, Mark J. Alles, Chairman and CEO of TORL, stated, "We are thrilled to welcome Anna to our Board. Her clinical insights and leadership in oncology are invaluable as we pursue our goal of revolutionizing cancer treatment. Her involvement will undoubtedly enhance our strategies for developing new therapies."
The Importance of Dr. Berkenblit’s Expertise
Her clinical and industry insights come at a crucial time for TORL as the company continues advancing its pipeline of oncology therapies, most notably the Claudin 6-targeted ADC TORL-1-23. Dennis Slamon, MD, PhD, a Board Member and Scientific Co-founder, noted, "Anna's expertise is especially timely as we expand our efforts in developing what could become the first-in-class cancer therapies based on monoclonal antibodies."
Throughout her career, Dr. Berkenblit has demonstrated her commitment to oncology by leading several successful trials and guiding teams in the launch of new treatments, positioning her as a respected figure in the biopharmaceutical community.
Further Career Contributions
Prior to her role with PanCAN, Dr. Berkenblit served as Senior Vice President of Clinical Development at H3 Biomedicine and led the Clinical Research department at Aveo Oncology. Her strategic roles at these companies have enriched her perspective and enhanced her capabilities in the field.
"Having Dr. Berkenblit onboard is a tremendous advantage for TORL as we advance our registrational Phase 2 CATALINA-2 trial of TORL-1-23 for Claudin 6-positive patients undergoing treatment," said Dave Licata, Co-founder and President of TORL. This trial remains a top priority for the company in the coming period.
Understanding Claudin 6 and Its Role in Cancer
Claudin 6 (CLDN6) is a critical target for cancer therapies due to its overexpression in various malignancies while being minimally expressed in normal tissues. This feature makes CLDN6 a prime candidate for antibody-drug conjugate (ADC) development. Its presence has been associated with negative survival outcomes in ovarian cancer, highlighting the importance of targeting this protein.
Introducing TORL-1-23
TORL-1-23 is a leading candidate in the realm of clinical-stage ADCs designed specifically for CLDN6-positive tumors. The U.S. Food and Drug Administration has granted it Fast Track Designation, which accelerates the development process. The company is actively enrolling patients for the pivotal Phase 2 CATALINA-2 study involving women with CLDN6-positive platinum-resistant ovarian cancer. The primary objective of this trial is to evaluate the drug's effectiveness in treating this challenging form of cancer.
The CATALINA-2 Study Explained
CATALINA-2 is an extensive, randomized, open-label Phase 2 trial exploring the efficacy of the novel CLDN6-targeted ADC TORL-1-23. The study focuses on women who have already been through one to three lines of therapy for their cancer. Its primary endpoint centers on measuring the objective response rate (ORR) through blinded independent reviews, while secondary endpoints will assess overall survival and safety, giving a comprehensive view of the drug's potential.
About TORL BioTherapeutics LLC
TORL BioTherapeutics is committed to transforming the landscape of cancer treatment. With a focus on developing innovative monoclonal antibodies and ADCs, the company utilizes a collaborative strategy with the Slamon Research Lab at UCLA. Together, they work towards introducing new therapies targeting untapped cancer pathways, aiming to provide better outcomes for patients worldwide.
Frequently Asked Questions
What is TORL BioTherapeutics known for?
TORL BioTherapeutics specializes in developing antibody-based therapies to treat various types of cancer.
Who is Dr. Anna Berkenblit?
Dr. Berkenblit is a notable medical professional with over two decades of experience in cancer drug development and is now a Board Member at TORL.
What is Claudin 6?
Claudin 6 is a protein overexpressed in certain cancers, making it a critical target for therapeutic development.
What is the purpose of the CATALINA-2 study?
The CATALINA-2 study is designed to evaluate the effectiveness of the ADC TORL-1-23 in treating women with Claudin 6-positive ovarian cancer.
What is the significance of TORL-1-23?
TORL-1-23 is a promising treatment for Claudin 6-positive tumors and has received Fast Track Designation from the FDA.
